| Bioactivity | Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19[1]. |
| Target | SARS-CoV-2, ACE2 |
| Invitro | Regdanvimab (CT-P59) (0-1000 ng/mL; 72 h) can neutralize Gamma, Delta and Epsilon variants with IC50s of 161.5-1237 ng/mL[1]. |
| In Vivo | Regdanvimab (CT-P59) (5-80 mg/kg; i.p.; single dose) 可以降低小鼠 Gamma 和 Delta 株的病毒负担[1]。 Animal Model: |
| Name | Regdanvimab |
| CAS | 2444308-95-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ryu DK, et al. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun. 2021 Nov 12;578:91-96. |